One To Watch

Neurogene

A New York-based clinical-stage biotechnology company developing AAV-based gene therapies for rare and devastating neurological diseases, with a lead program targeting Rett syndrome.

Company Overview

A New York-based clinical-stage biotechnology company developing AAV-based gene therapies for rare and devastating neurological diseases, with a lead program targeting Rett syndrome. Neurogene's mission is to translate the promise of genetic medicine into transformative treatments for patients and families affected by conditions where no meaningful options currently exist. The company applies adeno-associated virus (AAV) delivery technology alongside proprietary gene regulation strategies to address the root molecular causes of neurological disease.

Headquarters and Global Presence

Neurogene is headquartered in New York City, New York. The company maintains a research collaboration with the University of Edinburgh, extending its scientific reach into European biomedical and translational research for neurodevelopmental diseases.

Founding and History

Neurogene was founded by Rachel McMinn, Ph.D., whose personal connection to rare neurological disease — her older brother lives with an undiagnosed condition — was a direct catalyst for establishing the company. The company raised $68.5 million in a Series A financing round led by Samsara BioCapital, EcoR1 Capital, and Cormorant Asset Management, closing in mid-2024. Neurogene became publicly traded on the NASDAQ Global Market under the ticker NGNE in June 2024, following a merger with Neoleukin Therapeutics. Total funding raised to date stands at approximately $184 million.

Therapy Areas and Focus

Neurogene is focused exclusively on rare neurological diseases, a category historically underserved by both small-molecule and biologic approaches due to the complexity of central nervous system access and genetic heterogeneity. The company's programs target conditions with clear genetic etiology, where a corrective or modulatory gene therapy approach offers the prospect of disease modification rather than symptom management. Rett syndrome, the most advanced indication in the pipeline, is a severe neurodevelopmental disorder caused by mutations in the MECP2 gene, affecting predominantly girls and currently lacking any approved disease-modifying treatment.

Technology Platforms and Modalities

Neurogene's core technology platform is built on AAV-based gene therapy, using viral vectors to deliver functional genetic cargo to neurons in the central nervous system. A key challenge in Rett syndrome is the dosage sensitivity of the MECP2 gene — both deficiency and overexpression cause neurological harm — requiring precise regulation of transgene expression. Neurogene has developed a proprietary transgene regulation approach intended to maintain MECP2 expression within a therapeutic window, differentiating its strategy from earlier-generation MECP2 gene therapy programs. The company's research collaboration with the University of Edinburgh provides additional capabilities to refine and advance these platform technologies.

Key Pipeline and Programs

NGN-401 is Neurogene's lead asset, an AAV9-delivered gene therapy encoding MECP2 under a proprietary regulation system designed to achieve therapeutic expression without triggering MECP2 duplication toxicity. It is being evaluated in a Phase I/II clinical trial in patients with Rett syndrome. The program has generated both meaningful early signals of activity and a serious safety event: in November 2024, a patient dosed at the highest evaluated dose level of 3E15 vg on November 5 died from a treatment-related serious adverse event, representing a significant regulatory and clinical inflection point for the program. The trial has spanned multiple dose cohorts, and the company's path forward with NGN-401 will be shaped by its ongoing dialogue with regulators and a thorough review of the safety data across all dose levels. No additional pipeline candidates have been publicly disclosed at advanced stages, though Neurogene's platform and University of Edinburgh collaboration are positioned to support future programs across additional rare neurological indications.

Recent Developments

The most consequential recent event was the November 2024 death of a trial participant in the NGN-401 Phase I/II Rett syndrome study, attributable to a treatment-related serious adverse event at the 3E15 vg dose level — a development that placed the program under heightened scrutiny. In April 2026, Neurogene appointed Christy Shafer as chief commercial officer and Christine Mikail, J.D. to its board of directors, signaling continued organizational build-out toward potential commercialization. Julie Jordan was appointed chief medical officer in June 2024, coinciding with the company's NASDAQ listing. These leadership additions reflect Neurogene's effort to strengthen both its clinical execution and its commercial readiness as the NGN-401 program advances through its safety review.

Key Personnel

Rachel McMinn, Ph.D., serves as Founder and Chief Executive Officer. She founded the company drawing on both personal family experience with rare neurological disease and a professional background in drug development and investment. Julie Jordan serves as Chief Medical Officer, appointed in June 2024 to lead the clinical development strategy. Christy Shafer serves as Chief Commercial Officer, joining in April 2026 with recognized expertise in building commercial organizations in the rare disease space.

Strategic Partnerships

Neurogene's most notable external collaboration is with the University of Edinburgh, a world-recognized center for biomedical and translational research in neurodevelopmental diseases. This partnership provides research infrastructure and scientific expertise to support platform development and the identification of future program candidates. The company has not publicly disclosed major pharma licensing or co-development deals at this stage.

FAQ Section

Neurogene completed a merger with Neoleukin Therapeutics, closing in June 2024, which resulted in the combined entity trading on NASDAQ under the ticker NGNE. This reverse-merger structure offered a faster route to public markets and access to capital at a critical stage for the NGN-401 program. The transaction was accompanied by a $68.5 million Series A financing, providing the company with runway to advance its clinical programs.

MECP2 is unusual in that both underexpression — the mutation driving Rett syndrome — and overexpression cause distinct and serious neurological pathology. This narrow therapeutic window makes standard gene addition strategies risky, as viral-mediated overdelivery can cause MECP2 duplication syndrome. Neurogene's proprietary transgene regulation system is specifically designed to maintain expression within a safe and effective range, which is the central technical differentiator of NGN-401 versus earlier programs.

Neurogene's focus on dosage-sensitive targets like MECP2 — where a precision regulation layer is required over and above simple gene delivery — distinguishes it from programs relying on unregulated transgene expression. The company's exclusive focus on rare neurological diseases, combined with its University of Edinburgh partnership, allows it to build deep disease-specific expertise rather than spreading across multiple therapeutic areas. Its founder-led model, rooted in personal experience with neurological disease, also shapes a strong organizational commitment to the rare disease community.

NGN-401 is under evaluation in a Phase I/II clinical trial for Rett syndrome across multiple dose levels. In November 2024, a patient dosed at 3E15 vg — the highest evaluated dose level — died from a treatment-related serious adverse event, a significant safety signal that placed the high-dose cohort under scrutiny. The program's forward trajectory depends on the company's review of safety data across all dose levels and ongoing interactions with the FDA and other regulatory bodies.

Neurogene's pipeline is currently anchored in rare neurodevelopmental diseases, with Rett syndrome as the lead indication through NGN-401. The company's AAV-based platform and MECP2 regulation technology are designed to be adaptable to other neurological conditions characterized by genetic mutations with dosage sensitivity. The University of Edinburgh collaboration is positioned to support discovery work that could yield additional program candidates beyond NGN-401, though no further advanced-stage assets have been publicly disclosed.

Neurogene is a clinical-stage company, with NGN-401 in Phase I/II trials — placing it at one of the earlier but most data-generative stages of clinical development. The critical near-term milestone is a regulatory determination on the path forward for NGN-401 following the November 2024 fatality, including any dose restrictions or protocol modifications. The April 2026 appointment of a chief commercial officer suggests the leadership team is simultaneously planning for a potential path to approval, even as safety questions are being resolved.

Key watchpoints for Neurogene include:

Want to Update your Company's Profile?